Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Virbac

Market Cap 2.87B 3.31B 2.64B 2.48B 4.63B 317B 4.73B 31.55B 12.22B 153B 12.41B 12.15B 531B P/E Ratio 2026 *
17.1x
P/E Ratio 2027 * 15.2x
Enterprise Value 2.99B 3.45B 2.76B 2.58B 4.83B 330B 4.93B 32.88B 12.73B 159B 12.94B 12.66B 553B EV / Sales 2026 *
1.93x
EV / Sales 2027 * 1.77x
Free-Float
49.03%
Yield 2026 *
0.51%
Yield 2027 * 0.6%
1 day+6.04%
1 month+6.04%
3 months-6.49%
6 months-6.49%
Current year-6.49%
Current year 384.75
Extreme 384.75
408
1 year 384.75
Extreme 384.75
436.32
3 years 288
Extreme 288
436.32
5 years 288
Extreme 288
436.32
10 years 131
Extreme 131
436.32
Manager TitleAgeSince
Chief Executive Officer 46 01/09/2025
Chief Executive Officer 50 27/09/2024
Chief Operating Officer 64 01/01/2022
Director TitleAgeSince
Chairman 61 01/04/2006
Director/Board Member 68 28/07/2010
Director/Board Member 65 05/09/2017
Change 5-day change 1-year change 3-year change Capi.($)
+6.04%-.--% - - 3.32B
+0.14%+2.36%-51.06%-50.09% 34.08B
+5.16%-2.67%+68.54%+165.45% 11.42B
-0.79%-4.29%+3.93%+28.88% 4.6B
-1.08%+4.65%+58.22%+19.30% 1.95B
+3.11%+5.67%-31.24%+1.36% 1.61B
+0.26%-5.39%+28.17%+131.56% 1.26B
-2.39%-4.68%-29.40%-12.83% 1.04B
-2.07%+0.61%-6.10%-44.56% 1.02B
-0.85%+1.30%-4.76%-21.41% 949M
Average +0.75%-0.18%+4.03%+24.18% 6.44B
Weighted average by Cap. +1.27%+0.70%-15.22%+7.65%

Financials

2026 *2027 *
Net sales 1.55B 1.78B 1.43B 1.34B 2.5B 171B 2.55B 17B 6.58B 82.25B 6.69B 6.55B 286B 1.64B 1.89B 1.51B 1.42B 2.65B 181B 2.7B 18.03B 6.98B 87.2B 7.09B 6.94B 303B
Net income 167M 192M 154M 144M 270M 18.43B 275M 1.84B 711M 8.88B 723M 707M 30.89B 190M 219M 175M 164M 307M 20.99B 313M 2.09B 810M 10.12B 823M 805M 35.17B
Net Debt 121M 139M 112M 105M 195M 13.35B 199M 1.33B 515M 6.44B 523M 512M 22.38B 26.49M 30.53M 24.42M 22.88M 42.75M 2.92B 43.64M 291M 113M 1.41B 115M 112M 4.9B
Logo Virbac
Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows: - pet medications (60.7%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications (39.3%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: Europe (41.6%), Latin America (15.2%), North America (13.6%), India/Africa/Middle East (12.2%), Eastern Asia (10.5%) and Pacific (6.9%).
Employees
6,442
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
342.50EUR
Average target price
412.88EUR
Spread / Average Target
+20.55%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!